Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Oral Contraceptives with Retatrutide in Overweight Women
NCT06039826Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2023
- Primary completion
- Jul 2024
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of retatrutide in obesity and Overweight, sponsored by Eli Lilly and Company. Primary endpoints: Area Under the Concentration Versus Time Curve from Time zero to 24 Hours Postdose of Ethinyl Estradiol, Maximum Observed Concentration of Ethinyl Estradiol and 4 more. Started Sep 2023; status: completed.
02
Drugs
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT06039826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06039826.